Allogeneic transplantation improves the overall and progression-free survival of Hodgkin lymphoma patients relapsing after autologous transplantation: A retrospective study based on the time of HLA typing and donor availability

Barbara Sarina, Luca Castagna, Lucia Farina, Francesca Patriarca, Fabio Benedetti, Angelo M. Carella, Michele Falda, Stefano Guidi, Fabio Ciceri, Alessandro Bonini, Samantha Ferrari, Michele Malagola, Enrico Morello, Giuseppe Milone, Benedetto Bruno, Nicola Mordini, Simonetta Viviani, Alessandro Levis, Laura Giordano, Armando SantoroPaolo Corradini

Research output: Contribution to journalArticle

Abstract

Hodgkin lymphoma relapsing after autologous transplantation (autoSCT) has a dismal outcome. Allogeneic transplantation (alloSCT) using reduced intensity conditioning (RIC) is a salvage option, but its effectiveness is still unclear. To evaluate the role of RIC alloSCT, we designed a retrospective study based on the commitment of attending physicians to perform a salvage alloSCT; thus, only Hodgkin lymphoma patients having human leukocyte antigen-typing immediately after the failed autoSCT were included. Of 185 patients, 122 found an identical sibling (55%), a matched unrelated (32%) or a haploidentical sibling (13%) donor; 63 patients did not find any donor. Clinical features of both groups did not differ. Two-year progression-free (PFS) and overall survival (OS) were better in the donor group (39.3% vs 14.2%, and 66% vs 42%, respectively, P <.001) with a median follow-up of 48 months. In multivariable analysis, having a donor was significant for better PFS and OS (P <.001). Patients allografted in complete remission showed a better PFS and OS. This is the largest study comparing RIC alloSCT versus conventional treatment after a failed auto-SCT, indicating a survival benefit for patients having a donor.

Original languageEnglish
Pages (from-to)3671-3677
Number of pages7
JournalBlood
Volume115
Issue number18
DOIs
Publication statusPublished - May 6 2010

Fingerprint

Salvaging
Histocompatibility Testing
Autologous Transplantation
Homologous Transplantation
Hodgkin Disease
Disease-Free Survival
Retrospective Studies
Tissue Donors
Availability
HLA Antigens
Survival
Siblings
Physicians
Conditioning (Psychology)

ASJC Scopus subject areas

  • Hematology
  • Biochemistry
  • Cell Biology
  • Immunology

Cite this

Allogeneic transplantation improves the overall and progression-free survival of Hodgkin lymphoma patients relapsing after autologous transplantation : A retrospective study based on the time of HLA typing and donor availability. / Sarina, Barbara; Castagna, Luca; Farina, Lucia; Patriarca, Francesca; Benedetti, Fabio; Carella, Angelo M.; Falda, Michele; Guidi, Stefano; Ciceri, Fabio; Bonini, Alessandro; Ferrari, Samantha; Malagola, Michele; Morello, Enrico; Milone, Giuseppe; Bruno, Benedetto; Mordini, Nicola; Viviani, Simonetta; Levis, Alessandro; Giordano, Laura; Santoro, Armando; Corradini, Paolo.

In: Blood, Vol. 115, No. 18, 06.05.2010, p. 3671-3677.

Research output: Contribution to journalArticle

Sarina, Barbara ; Castagna, Luca ; Farina, Lucia ; Patriarca, Francesca ; Benedetti, Fabio ; Carella, Angelo M. ; Falda, Michele ; Guidi, Stefano ; Ciceri, Fabio ; Bonini, Alessandro ; Ferrari, Samantha ; Malagola, Michele ; Morello, Enrico ; Milone, Giuseppe ; Bruno, Benedetto ; Mordini, Nicola ; Viviani, Simonetta ; Levis, Alessandro ; Giordano, Laura ; Santoro, Armando ; Corradini, Paolo. / Allogeneic transplantation improves the overall and progression-free survival of Hodgkin lymphoma patients relapsing after autologous transplantation : A retrospective study based on the time of HLA typing and donor availability. In: Blood. 2010 ; Vol. 115, No. 18. pp. 3671-3677.
@article{04a54fce692c48d38dcb6cca0fbbbf23,
title = "Allogeneic transplantation improves the overall and progression-free survival of Hodgkin lymphoma patients relapsing after autologous transplantation: A retrospective study based on the time of HLA typing and donor availability",
abstract = "Hodgkin lymphoma relapsing after autologous transplantation (autoSCT) has a dismal outcome. Allogeneic transplantation (alloSCT) using reduced intensity conditioning (RIC) is a salvage option, but its effectiveness is still unclear. To evaluate the role of RIC alloSCT, we designed a retrospective study based on the commitment of attending physicians to perform a salvage alloSCT; thus, only Hodgkin lymphoma patients having human leukocyte antigen-typing immediately after the failed autoSCT were included. Of 185 patients, 122 found an identical sibling (55{\%}), a matched unrelated (32{\%}) or a haploidentical sibling (13{\%}) donor; 63 patients did not find any donor. Clinical features of both groups did not differ. Two-year progression-free (PFS) and overall survival (OS) were better in the donor group (39.3{\%} vs 14.2{\%}, and 66{\%} vs 42{\%}, respectively, P <.001) with a median follow-up of 48 months. In multivariable analysis, having a donor was significant for better PFS and OS (P <.001). Patients allografted in complete remission showed a better PFS and OS. This is the largest study comparing RIC alloSCT versus conventional treatment after a failed auto-SCT, indicating a survival benefit for patients having a donor.",
author = "Barbara Sarina and Luca Castagna and Lucia Farina and Francesca Patriarca and Fabio Benedetti and Carella, {Angelo M.} and Michele Falda and Stefano Guidi and Fabio Ciceri and Alessandro Bonini and Samantha Ferrari and Michele Malagola and Enrico Morello and Giuseppe Milone and Benedetto Bruno and Nicola Mordini and Simonetta Viviani and Alessandro Levis and Laura Giordano and Armando Santoro and Paolo Corradini",
year = "2010",
month = "5",
day = "6",
doi = "10.1182/blood-2009-12-253856",
language = "English",
volume = "115",
pages = "3671--3677",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "18",

}

TY - JOUR

T1 - Allogeneic transplantation improves the overall and progression-free survival of Hodgkin lymphoma patients relapsing after autologous transplantation

T2 - A retrospective study based on the time of HLA typing and donor availability

AU - Sarina, Barbara

AU - Castagna, Luca

AU - Farina, Lucia

AU - Patriarca, Francesca

AU - Benedetti, Fabio

AU - Carella, Angelo M.

AU - Falda, Michele

AU - Guidi, Stefano

AU - Ciceri, Fabio

AU - Bonini, Alessandro

AU - Ferrari, Samantha

AU - Malagola, Michele

AU - Morello, Enrico

AU - Milone, Giuseppe

AU - Bruno, Benedetto

AU - Mordini, Nicola

AU - Viviani, Simonetta

AU - Levis, Alessandro

AU - Giordano, Laura

AU - Santoro, Armando

AU - Corradini, Paolo

PY - 2010/5/6

Y1 - 2010/5/6

N2 - Hodgkin lymphoma relapsing after autologous transplantation (autoSCT) has a dismal outcome. Allogeneic transplantation (alloSCT) using reduced intensity conditioning (RIC) is a salvage option, but its effectiveness is still unclear. To evaluate the role of RIC alloSCT, we designed a retrospective study based on the commitment of attending physicians to perform a salvage alloSCT; thus, only Hodgkin lymphoma patients having human leukocyte antigen-typing immediately after the failed autoSCT were included. Of 185 patients, 122 found an identical sibling (55%), a matched unrelated (32%) or a haploidentical sibling (13%) donor; 63 patients did not find any donor. Clinical features of both groups did not differ. Two-year progression-free (PFS) and overall survival (OS) were better in the donor group (39.3% vs 14.2%, and 66% vs 42%, respectively, P <.001) with a median follow-up of 48 months. In multivariable analysis, having a donor was significant for better PFS and OS (P <.001). Patients allografted in complete remission showed a better PFS and OS. This is the largest study comparing RIC alloSCT versus conventional treatment after a failed auto-SCT, indicating a survival benefit for patients having a donor.

AB - Hodgkin lymphoma relapsing after autologous transplantation (autoSCT) has a dismal outcome. Allogeneic transplantation (alloSCT) using reduced intensity conditioning (RIC) is a salvage option, but its effectiveness is still unclear. To evaluate the role of RIC alloSCT, we designed a retrospective study based on the commitment of attending physicians to perform a salvage alloSCT; thus, only Hodgkin lymphoma patients having human leukocyte antigen-typing immediately after the failed autoSCT were included. Of 185 patients, 122 found an identical sibling (55%), a matched unrelated (32%) or a haploidentical sibling (13%) donor; 63 patients did not find any donor. Clinical features of both groups did not differ. Two-year progression-free (PFS) and overall survival (OS) were better in the donor group (39.3% vs 14.2%, and 66% vs 42%, respectively, P <.001) with a median follow-up of 48 months. In multivariable analysis, having a donor was significant for better PFS and OS (P <.001). Patients allografted in complete remission showed a better PFS and OS. This is the largest study comparing RIC alloSCT versus conventional treatment after a failed auto-SCT, indicating a survival benefit for patients having a donor.

UR - http://www.scopus.com/inward/record.url?scp=77952574651&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77952574651&partnerID=8YFLogxK

U2 - 10.1182/blood-2009-12-253856

DO - 10.1182/blood-2009-12-253856

M3 - Article

C2 - 20220116

AN - SCOPUS:77952574651

VL - 115

SP - 3671

EP - 3677

JO - Blood

JF - Blood

SN - 0006-4971

IS - 18

ER -